FDA approves new Alzheimer’s treatment, donanemab from Eli Lilly
The Food and Drug Administration approved a new Alzheimer’s treatment called donanemab on Tuesday, clearing the way for the third addition to a new class of drugs aimed at slowing the brain’s decline in patients facing the early stages of the disease. Branded as Kisunla by drugmaker Eli Lilly, donanemab’s approval follows years of setbacks
Read More